10 research outputs found
HOMA-IR score in NAFL and NASH patients.
<p>*The HOMA-IR score in both NAFL and NASH patients exceeded the diagnostic criteria for insulin resistance.</p
Histological scores [mean±SD] according to Kleiner score in our study population.
<p>(*NAS: NAFLD activity score).</p
Prevalence of NAFLD, NASH and cirrhosis in patients undergone to liver biopsy.
<p>(NA: Not Applicable).</p
Distribution of the histological diagnosis on the basis of liver biopsy (NAFL, non-alcoholic fatty liver: Simple steatosis without necroinflammation and fibrosis; NASH: Non-alcoholic steatohepatitis; No NAFLD: No histologic signs of steatosis/steatohepatitis).
<p>Distribution of the histological diagnosis on the basis of liver biopsy (NAFL, non-alcoholic fatty liver: Simple steatosis without necroinflammation and fibrosis; NASH: Non-alcoholic steatohepatitis; No NAFLD: No histologic signs of steatosis/steatohepatitis).</p
Demographical, clinical and laboratory parameters of study population.
<p>(Data presented as mean (+ standard deviation) except where indicated differently.* Cirrhosis diagnosis: 3 clinical, 13 by liver biopsy.</p
Modifications of liver disease stage following DAA treatment in patients with cirrhosis.
<p>(A) Baseline, post-failure and post-retreatment SVR12 changes of Child Pugh Class; (B) baseline and post-failure changes of Child Pugh Class for patients who were not retreated yet; (C) baseline and post-SVR12 changes of Child Pugh Class for patients who achieved SVR12 following the first DAA treatment. Bold arrows indicate patients who did not change the Child Pugh Class. Dashed arrows indicate patients who worsened the Child Pugh Class, whereas the grey arrows indicate patients who improved the Child Pugh class. In the curly brackets are reported the number of patients for specific changes observed in the Child Pugh classes in the three points of evaluation. n = number of patients.</p
Univariate and logistic regression analysis linking failure with independent variables.
<p>Univariate and logistic regression analysis linking failure with independent variables.</p
Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).
<p>Failure rates following the first DAA regimen, by HCV genotype and treatment regimen in patients who completed the 12 weeks post treatment evaluation (n = 3,830 patients).</p
Characteristics of the study patients according to SVR following the first DAA treatment.
<p>Characteristics of the study patients according to SVR following the first DAA treatment.</p